Tissue and organ engineering: Investor sentiments and analysis

IF 4 3区环境科学与生态学 Q3 CELL & TISSUE ENGINEERING

Regenerative Therapy Pub Date : 2026-03-01 Epub Date: 2026-01-12 DOI:10.1016/j.reth.2026.101066

Frida Velcani , Erica Keyes , José Luis Caraveo III , James Reohr , Craig D'Cruz , Andrew Osterman , Deirdre C. O'Donnell

{"title":"Tissue and organ engineering: Investor sentiments and analysis","authors":"Frida Velcani , Erica Keyes , José Luis Caraveo III , James Reohr , Craig D'Cruz , Andrew Osterman , Deirdre C. O'Donnell","doi":"10.1016/j.reth.2026.101066","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Regenerative medicine involves restoring natural function by replacing or regenerating human cells, tissues, or organs. Despite projections of significant market growth, venture capital (VC) investment in tissue and organ engineering has recently declined.</div></div><div><h3>Methods</h3><div>We conducted a mixed-methods study using structured surveys and qualitative interviews. VC investors with experience in healthcare sectors (biotechnology, tissue engineering, and medical technology) were invited to complete a survey and participate in interviews.</div></div><div><h3>Results</h3><div>We received 22 survey responses and conducted 9 interviews (April–May 2025). Prior exposure to regenerative medicine was significantly associated with future investment likelihood (p = 0.0464). Investment potential strongly correlated with assets under management (ρ = 0.67) and investment stage (ρ = 0.66). Among 20 respondents, clinical validation (n = 8) and adoption (n = 8) were most often cited as major investment drivers, followed by reimbursement and regulatory challenges. Interviews emphasized four factors shaping VC interest in tissue and organ engineering: prior investment experience, time horizon misalignment, clinical risk expectations, and market readiness.</div></div><div><h3>Discussion</h3><div>Startups can improve appeal by targeting long-horizon investors, outlining clinical and regulatory pathways, and generating robust, comparative evidence to support value-based reimbursement.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"31 ","pages":"Article 101066"},"PeriodicalIF":4.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative Therapy","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352320426000076","RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Regenerative medicine involves restoring natural function by replacing or regenerating human cells, tissues, or organs. Despite projections of significant market growth, venture capital (VC) investment in tissue and organ engineering has recently declined.

Methods

We conducted a mixed-methods study using structured surveys and qualitative interviews. VC investors with experience in healthcare sectors (biotechnology, tissue engineering, and medical technology) were invited to complete a survey and participate in interviews.

Results

We received 22 survey responses and conducted 9 interviews (April–May 2025). Prior exposure to regenerative medicine was significantly associated with future investment likelihood (p = 0.0464). Investment potential strongly correlated with assets under management (ρ = 0.67) and investment stage (ρ = 0.66). Among 20 respondents, clinical validation (n = 8) and adoption (n = 8) were most often cited as major investment drivers, followed by reimbursement and regulatory challenges. Interviews emphasized four factors shaping VC interest in tissue and organ engineering: prior investment experience, time horizon misalignment, clinical risk expectations, and market readiness.

Discussion

Startups can improve appeal by targeting long-horizon investors, outlining clinical and regulatory pathways, and generating robust, comparative evidence to support value-based reimbursement.

查看原文本刊更多论文

组织和器官工程：投资者情绪和分析

再生医学涉及通过替换或再生人体细胞、组织或器官来恢复自然功能。尽管预计市场将大幅增长，但组织和器官工程领域的风险资本（VC）投资最近有所下降。方法采用结构化调查和定性访谈相结合的研究方法。具有医疗保健行业（生物技术、组织工程和医疗技术）经验的风险投资者被邀请完成一项调查并参与访谈。结果共收到22份调查问卷，进行了9次访谈（2025年4 - 5月）。先前接触再生医学与未来投资可能性显著相关（p = 0.0464）。投资潜力与管理资产规模（ρ = 0.67）和投资阶段（ρ = 0.66）有很强的相关性。在20个受访者中，临床验证（n = 8）和采用（n = 8）最常被认为是主要的投资驱动因素，其次是报销和监管挑战。访谈强调了影响风险投资对组织和器官工程兴趣的四个因素：先前的投资经验、时间范围偏差、临床风险预期和市场准备情况。初创公司可以通过瞄准长线投资者，概述临床和监管途径，并产生强有力的比较证据来支持基于价值的报销，从而提高吸引力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative Therapy Engineering-Biomedical Engineering

CiteScore

6.00

自引率

2.30%

发文量

106

审稿时长

49 days

期刊介绍： Regenerative Therapy is the official peer-reviewed online journal of the Japanese Society for Regenerative Medicine. Regenerative Therapy is a multidisciplinary journal that publishes original articles and reviews of basic research, clinical translation, industrial development, and regulatory issues focusing on stem cell biology, tissue engineering, and regenerative medicine.